Previous Article | Next Article ![]()
Journal of Virology, April 1999, p. 3292-3300, Vol. 73, No. 4
Department of Virology, Biomedical Primate
Research Center, Rijswijk, The Netherlands1;
Chiron Corporation, Emeryville,
California2; Department of Virology, The
National Veterinary Institute, Uppsala,
Sweden3; and PowderJect Vaccines,
Inc., Madison, Wisconsin4
Received 13 July 1998/Accepted 5 January 1999
The kinetics of T-helper immune responses generated in 16 mature
outbred rhesus monkeys (Macaca mulatta) within a 10-month period by three different human immunodeficiency virus type 1 (HIV-1)
vaccine strategies were compared. Immune responses to monomeric
recombinant gp120SF2 (rgp120) when the protein was
expressed in vivo by DNA immunization or when it was delivered as a
subunit protein vaccine formulated either with the MF59 adjuvant or by incorporation into immune-stimulating complexes (ISCOMs) were compared.
Virus-neutralizing antibodies (NA) against HIV-1SF2 reached
similar titers in the two rgp120SF2 protein-immunized groups, but the responses showed different kinetics, while NA were
delayed and their levels were low in the DNA-immunized animals. Antigen-specific gamma interferon (IFN-
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Comparison of Immunity Generated by Nucleic Acid-,
MF59-, and ISCOM-Formulated Human Immunodeficiency Virus Type 1 Vaccines in Rhesus Macaques: Evidence for Viral Clearance
) T-helper (type 1-like) responses were detected in the DNA-immunized group, but only after the
fourth immunization, and the rgp120/MF59 group generated both IFN-
and interleukin-4 (IL-4) (type 2-like) responses that appeared after
the third immunization. In contrast, rgp120/ISCOM-immunized animals
rapidly developed marked IL-2, IFN-
(type 1-like), and IL-4
responses that peaked after the second immunization. To determine which
type of immune responses correlated with protection from infection, all
animals were challenged intravenously with 50 50% infective doses of a
rhesus cell-propagated, in vivo-titrated stock of a chimeric simian
immunodeficiency virus-HIVSF13 construct. Protection was
observed in the two groups receiving the rgp120 subunit vaccines. Half
of the animals in the ISCOM group were completely protected from
infection. In other subunit vaccinees there was evidence by multiple
assays that virus detected at 2 weeks postchallenge was effectively
cleared. Early induction of potent type 1- as well as type 2-like
T-helper responses induced the most-effective immunity.
*
Corresponding author. Mailing address: Department of
Virology, Biomedical Primate Research Center, P.O. Box 3306, 2280 GH Rijswijk, The Netherlands. Phone: 31 15 284 26 61. Fax: 31 15 284 39 86. E-mail: heeney{at}bprc.nl.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|